Genital Herpes Clinical Trial
Official title:
Effects of Melatonin in the Treatment of Genital Herpes
Genital herpes is a common and increasingly-common infection worldwide. The annual incidence in the United States is 1.75 per 1000 inhabitants. The etiologic agent is the herpes type 1 and 2 strains simplex virus. Classical Treatment is with acyclovir which decreases the duration of the disease and prevents rashes but has no curative effect. Also, studies show herpes resistance to acyclovir which has stimulating research into new drugs to treat this condition. Authors suggest melatonin way be a therapeutic agent in herpetic disease due to its modulatory action in immune and inflammatory responses when administered in adequate doses. Therefore, the aim of this study is to evaluate the effects of melatonin in the treatment of genital herpes as well as compare it to acyclovir in a double-blind, prospective and randomized, investigation. Outcome measures will include clinical evaluation of patients and laboratory endpoints.
The authors have investigate the relationship of estrogen-dependent malignant tumors with reduced levels of melatonin. It is speculated that the indoleamine can be classified as anti-estrogenic drug, both by its action on estrogen synthesis with aromatase inhibition and by its interference with estrogen receptors. Experimentally melatonin prevents promotion and growth of mammary tumors in rodents, probably by interacting with epithelial cell receptor; increasing local immunity by acting as an antioxidant agent and by inhibiting telomerase activity in tumor cells . ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06033261 -
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
|
Phase 1/Phase 2 | |
Completed |
NCT00362297 -
Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
|
Phase 4 | |
Completed |
NCT01132729 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
|
N/A | |
Completed |
NCT01132716 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions
|
N/A | |
Terminated |
NCT01658826 -
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
|
Phase 2 | |
Completed |
NCT00262106 -
Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection
|
Phase 3 | |
Completed |
NCT01346475 -
Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
|
Phase 4 | |
Completed |
NCT01390805 -
Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)
|
N/A | |
Terminated |
NCT03146403 -
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
|
Phase 2 | |
Completed |
NCT03080961 -
The VIBLOK SAfety and perFormancE Trial
|
N/A | |
Completed |
NCT00231049 -
Trial Evaluating Safety, Tolerability and Immune Response of AG-707
|
Phase 1 | |
Completed |
NCT00306787 -
Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes
|
Phase 3 | |
Completed |
NCT00495573 -
HSV-2 Shedding Resolution After Acyclovir Treatment
|
N/A | |
Completed |
NCT00477334 -
Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients
|
Phase 4 | |
Not yet recruiting |
NCT03595995 -
A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621
|
Phase 2 | |
Completed |
NCT01281007 -
Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes
|
Phase 3 | |
Completed |
NCT01112956 -
Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2
|
N/A | |
Completed |
NCT00129818 -
A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding
|
Phase 4 | |
Completed |
NCT00808405 -
GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women
|
N/A | |
Terminated |
NCT00495716 -
Effect of HSV-2 Suppressive Therapy on Sexual Behavior
|
Phase 4 |